Edgewise Therapeutics Inc

NASDAQ EWTX

Data sourced from

and

Download Data

Edgewise Therapeutics Inc Tangible Asset Value Ratio for the year ending December 31, 2023

Edgewise Therapeutics Inc Tangible Asset Value Ratio is NA for the year ending December 31, 2023. The tangible asset value ratio measures the proportion of tangible assets to total assets. It is calculated by dividing the tangible assets by the total assets. This ratio indicates the significance of tangible assets, such as property, plant, and equipment, in the company's total asset structure. A higher ratio suggests a higher proportion of tangible assets relative to total assets.

Edgewise Therapeutics Inc Tangible Asset Value Ratio for the year ending December 31, 2022 was 0.94, a -1.82% change year over year.
Edgewise Therapeutics Inc Tangible Asset Value Ratio for the year ending December 31, 2021 was 0.96, a 477.46% change year over year.
Edgewise Therapeutics Inc Tangible Asset Value Ratio for the year ending December 31, 2020 was -0.25, a 62.89% change year over year.
Edgewise Therapeutics Inc Tangible Asset Value Ratio for the year ending December 31, 2019 was -0.69.

NASDAQ: EWTX

Edgewise Therapeutics Inc

CEO	Dr. Kevin Koch Ph.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	3415 Colorado Avenue, Boulder, CO, United States, 80303
Employees	92
Sector	Healthcare
Industry	Biotechnology

Description

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key trends